Molecular profile of breast versus ovarian cancer cells in response to treatment with the anticancer drugs cisplatin, carboplatin, doxorubicin, etoposide and taxol

Biological Chemistry

Volumn 389, Issue 11, 2008, Pages 1427-1434

  Thomadaki, Hellinida ^a   Scorilas, Andreas ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

BAX; BCL2; BCL2L12; CASPASE 3; FAS; GAPDH

Indexed keywords

BCL2L12 PROTEIN; CARBOPLATIN; CASPASE 3; CELL PROTEIN; CISPLATIN; COMPLEMENTARY DNA; DOXORUBICIN; ETOPOSIDE; FAS ANTIGEN; MESSENGER RNA; PACLITAXEL; PRIMER DNA; PROTEIN BAX; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; GENE AMPLIFICATION; HOUSEKEEPING GENE; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; OVARY CANCER; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CARBOPLATIN; CELL LINE, TUMOR; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; RNA, MESSENGER;

EID: 56549102100     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/BC.2008.161     Document Type: Article

References (34)

1. Barry, M.A., Behnke, C.A., and Eastman, A. (1990). Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem. Pharmacol. 40, 2353-2362.
2. Bewick, M., Conlon, M., Parissenti, A.M., Lee, H., Zhang, L., Glück, S., and Lafrenie, R.M. (2001). Soluble Fas (CD95) is a prognostic factor in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous stem cell transplantation. J. Hematother. Stem Cell Res. 10, 759-768.
3. Bohm, I. and Schild, H. (2003). Apoptosis: the complex scenario for a silent cell death. Mol. Imaging Biol. 5, 2-14.
4. Botti, C., Buglioni, S., Benevolo, M., Giannarelli, D., Papaldo, P., Cognetti, F., Vici, P., Di Filippo, F., Del Nonno, F., Venanzi, F.M., et al. (2004). Altered expression of FAS system is related to adverse clinical outcome in stage I-II breast cancer patients treated with adjuvant anthracycline-based chemotherapy. Clin. Cancer Res. 10, 1360-1365.
5. Cardoso, F., Paesmans, M., Larsimont, D., Durbecq, V., Bernard-Marty, C., Rouas, G., Dolci, S., Sotiriou, C., Piccart, M.J., and Di Leo, A. (2004). Potential predictive value of Bcl-2 for response to tamoxifen in the adjuvant setting of node-positive breast cancer. Clin. Breast Cancer 5, 364-369.
6. Ciocca, D.R. and Elledge, R. (2000). Molecular markers for predicting response to tamoxifen in breast cancer patients. Endocrine 13, 1-10.
7. Daidone, M.G., Luisi, A., Veneroni, S., Benini, E., and Silvestrini, R. (1999). Clinical studies of Bcl-2 and treatment benefit in breast cancer patients. Endocr. Relat. Cancer 6, 61-68.
8. Fadeel, B. (2003). Programmed cell clearance. Cell Mol. Life Sci. 60, 2575-2585.
9. Floros, K.V., Thomadaki, H., Lallas, G., Katsaros, N., Talieri, M., and Scorilas, A. (2003). Cisplatin-induced apoptosis in HL-60 human promyelocytic leukemia cells: differential expression of BCL2 and novel apoptosis-related gene BCL2L12. Ann. NY Acad. Sci. 1010, 153-158.
10. Floros, K.V., Thomadaki, H., Katsaros, N., Talieri, M., and Scorilas, A. (2004). mRNA expression analysis of a variety of apoptosis-related genes, including the novel gene of the BCL2-family, BCL2L12, in HL-60 leukemia cells after treatment with carboplatin and doxorubicin. Biol. Chem. 385, 1099-1103.
11. Floros, K.V., Talieri, M., and Scorilas, A. (2006a). Topotecan and methotrexate alter expression of the apoptosis-related genes BCL2, FAS and BCL2L12 in leukemic HL-60 cells. Biol. Chem. 387, 1629-1633.
12. Floros, K.V., Thomadaki, H., Florou, D., Talieri, M., and Scorilas, A. (2006b). Alterations in mRNA expression of apoptosis-related genes BCL2, BAX, FAS, caspase-3, and the novel member BCL2L12 after treatment of human leukemic cell line HL60 with the antineoplastic agent etoposide. Ann. NY Acad. Sci. 1090, 89-97.
13. Kolfschoten, G.M., Hulscher, T.M., Duyndam, M.C., Pinedo, H.M., and Boven, E. (2002a). Variation in the kinetics of caspase-3 activation, Bcl-2 phosphorylation and apoptotic morphology in unselected human ovarian cancer cell lines as a response to docetaxel. Biochem. Pharmacol. 63, 733-743.
14. Kolfschoten, G.M., Hulscher, T.M., Schrier, S.M., van Houten, V.M., Pinedo, H.M., and Boven, E. (2002b). Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin. Gynecol. Oncol. 84, 404-412.
15. Kurokawa, H., Nishio, K., Fukumoto, H., Tomonari, A., Suzuki, T., and Saijo, N. (1999). Alteration of caspase-3 (CPP32/Yama/apopain) in wild-type MCF-7 breast cancer cells. Oncol. Rep. 6, 33-37.
16. Lennon, S.V., Martin, S.J., and Cotter, T.G. (1991). Dose-dependent induction of apoptosis in human tumour cell lines by widely diverging stimuli. Cell. Prolif. 24, 203-214.
17. Linke, S.P., Bremer, T.M., Herold, C.D., Sauter, G., and Diamond, C.A. (2006). Multimarker model to predict outcome in tamoxifen-treated breast cancer patients. Clin. Cancer Res. 12, 1175-1183.
18. Mandlekar, S., Yu, R., Tan, T.H., and Kong, A.N. (2000). Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells. Cancer Res. 60, 5995-6000.
19. Mathioudaki, K., Scorilas, A., Papadokostopoulou, A., Xynopoulos, D., Arnogianaki, N., Agnanti, N., and Talieri, M. (2004). Expression analysis of BCL2L12, a new member of apoptosis-related genes, in colon cancer. Biol. Chem. 385, 779-783.
20. McKenna, S.L., McGowan, A.J., and Cotter, T.G. (1998). Molecular mechanisms of programmed cell death. Adv. Biochem. Eng. Biotechnol. 62, 1-31.
21. Mieog, J.S., van der Hage, J.A., van de Vijuer, M.J., and van de Velde, C.J. (2006). Cooperating Investigators of the EORTC. Tumour response to preoperative anthracycline-based chemotherapy in operable breast cancer: the predictive role of p53 expression. Eur. J. Cancer 42, 1369-1379.
22. Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55-63.
23. Müllauer, L., Mosberger, I., Grusch, M., Rudas, M., and Chott, A. (2000). Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer. J. Pathol. 191, 468-470.
24. Otsuki, Y., Li, Z., and Shibata, M.A. (2003). Apoptotic detection methods - from morphology to gene. Prog. Histochem. Cytochem. 38, 275-339.
25. Pusztai, L., Krishnamurti, S., Perez Cardona, J., Sneige, N., Esteva, F.J., Volchenok, M., Breitenfelder, P., Kau, S.W., Takayama, S., Krajewski, S., et al. (2004). Expression of BAG-1 and BcL-2 proteins before and after neoadjuvant chemotherapy of locally advanced breast cancer. Cancer Invest. 22, 248-256.
26. Ravaioli, A., Bagli, L., Zucchini, A., and Monti, F. (1998). Prognosis and prediction of response in breast cancer: the current role of the main biological markers. Cell Prolif. 31, 113-126.
27. Sen, S. (1992). Programmed cell death: concept, mechanism and control. Biol. Rev. Camb. Philos. Soc. 67, 287-319.
28. Sjöström, J., Blomqvist, C., von Boguslawski, K., Bengtsson, N.O., Mjaaland, I., Malmström, P., Ostenstadt, B., Wist, E., Valvere, V., Takayama, S., et al. (2002). The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer. Clin. Cancer Res. 8, 811-816.
29. Stegh, A.H., Kim, H., Bachoo, R.M., Forloney, K.L., Zhang, J., Schulze, H., Park, K., Hannon, G.J., Yuan, J., Louis, D.N., et al. (2007). Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma. Genes Dev. 21, 98-111.
30. Talieri, M., Diamandis, E.P., Katsaros, N., Gourgiotis, D., Scorilas, A. (2003). Expression of BCL2L12, a new member of apoptosis-related genes, in breast tumors. Thromb. Haemost. 89, 1081-1088.
31. Thomadaki, H. and Scorilas, A. (2006). BCL2 family of apoptosis-related genes: functions and clinical implications in cancer. Crit. Rev. Clin. Lab. Sci. 43, 1-67.
32. Thomadaki, H. and Scorilas, A. (2007). Breast cancer cells response to the antineoplastic agents cisplatin, carboplatin, and doxorubicin at the mRNA expression levels of distinct apoptosis-related genes, including the new member, BCL2L12. Ann. NY Acad. Sci. 1095, 35-44.
33. Thomadaki, H., Talieri, M., and Scorilas, A. (2006). Treatment of MCF-7 cells with taxol and etoposide induces distinct alterations in the expression of apoptosis-related genes BCL2, BCL2L12, BAX, CASPASE-9 and FAS. Biol. Chem. 387, 1081-1086.
34. Thomadaki, H., Talieri, M., and Scorilas, A. (2007). Prognostic value of the apoptosis related genes BCL2 and BCL2L12 in breast cancer. Cancer Lett. 247, 48-55.